Formulary Watch |

Antigen tests, a new category, have a major advantage and disadvantage over COVID-19 tests already approved.

Numerous PPEs and testing kits also feature unproven coronavirus claims.

Formulation could cause fewer administration-related reactions than IV Darzalex.

Popular heartburn medication now in shortage due to COVID-19 test.

Agency says the anti-malaria drug can cause heart rhythm problems.

Suppliers claim CBD can help alleviate opioid addiction, cure diseases.

The drug, plus chemotherapy, shows a significant survival benefit.

Hospitals could receive $75 billion in funding to combat coronavirus.

Olumiant trial joins other RA drug trials, including hydroxychloroquine.

An NIH trial on the controversial anti-malaria medication is underway.

More COVID-19 patients receive anti-malaria drug despite controversy.

Agency issues Emergency Use Authorization for hydroxychloroquine sulfate, along with a novel COVID-19 test.

Clinical trial results were similar to those of the drug in adults.

First point-of-care test to detect coronavirus cleared.

The agency takes other steps to make COVID-19 tests more available.

New measures taken due to depression, suicidal thoughts, and other adverse events.

Discover the latest news on COVID-19 vaccine and drug development.

Companies cited over false coronavirus claims include The Jim Bakker Show.

Isatuximab-irfc (Sarclisa, Sanofi-Aventis) was approved in combination with pomalidomide and dexamethason to treat adult patients with multiple myeloma who have received at least two prior therapies.

Inhaler is the first generic approval of its kind.

Express Scripts’ annual Drug Trend Report highlights top contributors to prescription drug spending in 2019.

Treatment is first non-statin LDL-C lowering treatment approved in years.

Eisai disagrees with FDA decision.

Treatments include meds for arthritis pain and allergy eye drops.

Treatment will be first to target a specific type of advanced lung cancer.

FDA cleared the first generic sodium iodide product to treat hyperthyroidism and carcinoma of the thyroid.

FDA's Center for Drug Evaluation and Research approved fewer new treatments in 2019.

Global market for peanut allergy treatments estimate at $4.5 billion.

A new class of drugs for high cholesterol and a novel peanut allergy treatment lead expected approvals.

Novel cancer drug snags FDA approval.